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Background
Bare lymphocyte syndrome (BLS) is a rare, hereditary
immunodeficiency characterized by the absence of
major histocompatibility complex (MHC) class II lead-
ing to a form of severe combined immunodeficiency
(SCID). Here we present a case introducing BLS in a
novel population and emphasize some of the difficulties
faced in diagnosing and treating this condition.
Case
Our patient was a male of Dene native background from
the Northwest Territories of Canada. Between the ages of
2 weeks to 6 months of age he had multiple bouts of both
viral and bacterial pneumonia, two episodes of bacteremia,
and showed poor growth. Despite a low lymphocyte count
of 0.9 x 109 cells/L and undetectable immunoglobulins, an
immunologist was not initially consulted.
Finally, after his fifth episode of pneumonia he was
referred to the Immunology Department in Edmonton
and then transferred to the Alberta Children’s Hospital in
Calgary. Initial testing revealed IgG levels < 2 g/L, unde-
tectable IgM/IgA and poor response to the diphtheria and
tetanus vaccines. Flow cytometry revealed low CD3, CD4
and CD19 counts but normal NK and CD8 counts.
Thymidine mitogen testing for T-cell function was low
however T-cell receptor excision circle (TREC) analysis
was normal. An open thymic biopsy showed evidence of
CD4+ maturation arrest. Based on this, MHC class II
expression was investigated looking for HLA-DR proteins
by flow cytometry and were found to be absent.
A suitable bone marrow donor could not be found. Due
to the patient’s deteriorating course, a high resolution
hematopoietic stem cell transplantation using a 5/6 umbi-
lical cord donor was performed. Unfortunately, engraft-
ment failed and the child passed away at 19 months of age
secondary to respiratory failure.
The genetic testing came back posthumously showing
MHC class II deficiency with a RFX5 gene mutation
(R400X (1198 c>t).
Discussion
BLS is extremely rare with less than 200 reported cases
worldwide [1] and can result from mutations in one of
four regulatory proteins necessary for MHC-II production:
CIITA, RFX5, RFXANK and RFXAP [2]. This condition
leads to severe CD4+ T-cell dysfunction and thus recur-
rent bacterial, viral and protozoal infections. Recently
TREC studies have begun to be used as part of newborn
screening programs for SCID. While sensitive for nearly
all forms of SCID [3,4], TREC studies may be normal in
BLS [5].
Our case is the first of BLS identified in the Dene native
population. Given that early BMT has been shown to have
better success rates in treating BLS [6], a screening
program may be beneficial in this population.
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